Physician profile
Prince Daniel
NPI 1184111601
$1,131.28
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.33 | 2021 | |
| Biogen, INC. | $224.93 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $146.61 | 2021 | |
| Neurocrine Biosciences, INC. | $124.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.46 | 2021 | |
| Ucb, INC. | $123.52 | 2021 | |
| Alexion Pharmaceuticals, INC. | $121.67 | 2021 | |
| Baxter Healthcare | $15.99 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prince Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.